Introduction
The rates of mental illness among people with intellectual disability are at least 2.5 times higher than in the general population. 1 It is a significant concern that this mental illness is often undetected. 2 Challenges include communication difficulties, atypical presentations, coordinating multidisciplinary care, and the paucity of specialist intellectual disability mental health services.
The inappropriate use of psychotropics is common and includes overuse of psychotropic drugs to treat challenging behaviour, excessive dosage and duration of treatment, and polypharmacy. There is often inadequate monitoring of adverse effects.
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Non-drug management strategies
Psychological and environmental management of mental illness and challenging behaviour is preferable to using psychotropic drugs and in most situations it is indicated as a first-or second-line treatment. The evidence base supporting the use of psychological therapies for mental illness in people with intellectual disability is small but growing. There is growing evidence for the efficacy of cognitive behaviour therapy and mindfulness in the treatment of mood, anxiety disorders and obsessive compulsive disorders. Other psychotherapies, including dialectic behaviour therapy to treat personality disorders, may also be effective in some patients with mild to
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Full text free online at nps.org.au/australianprescriber VOLUME 39 : NUMBER 4 : AUGUST 2016 problems should be excluded before proceeding to diagnose and treat mental illness or challenging behaviour. If urgent intervention is required, drug use should be reviewed carefully once test results are available. The physical illnesses associated with particular syndromes may also affect the choice of drug (see Table 1 ). For example, potential interactions with commonly co-prescribed drugs such as anticonvulsants should be considered before prescribing.
The adverse effects of each psychotropic drug should be considered carefully, particularly in people with an elevated risk of cardiometabolic disease. Monitoring in people with intellectual disability requires a holistic and multidisciplinary approach that addresses dietary, lifestyle, socioeconomic, medical be modified for people with intellectual disability. 1 Additional caution is necessary due to the high number of medical comorbidities, communication barriers, and the complexity of care coordination. 1 The Box summarises key considerations when prescribing psychotropic drugs.
Comorbidity
People with intellectual disability have a significantly elevated incidence of physical health problems. 8 Unrecognised physical illness can result directly in mental illness or indirectly in challenging behaviour. Common problems include epilepsy and disorders causing pain (constipation, gastro-oesophageal reflux disease, musculoskeletal disorders and dental disease). Where possible, physical health Box Key considerations when prescribing psychotropic drugs to people with intellectual disability
Before prescribing
Determine that prescription is warranted based on:
• confirmed diagnosis of mental illness for which psychotropics are indicated
• challenging behaviour that is severe and non-responsive to maximal cognitive or behavioural therapy
• potential benefits that outweigh the harm
• discussion with carer.
Develop a treatment plan detailing:
• the person's communication needs
• targeted behaviour/symptom, frequency and intensity
• method of measurement of impact of drugs on these behaviours/ symptoms including how effects and adverse effects will be assessed
• all previous assessments of medical, psychiatric and functional causes of the behaviour or symptom
• past response to treatment including adverse effects
• a treatment timeline and contingency plan if ineffective.
Obtain consent from the individual or appointed decision maker.
Drug choice
Consider medical comorbidities and potential drug interactions including:
• syndromes that have an increased frequency of cardiometabolic, respiratory disorders or dementia -avoid drugs that will worsen these
• epilepsy -additional epilepsy monitoring may be required when prescribing psychotropics that lower the seizure threshold. Consider also the potential for some anticonvulsants to induce metabolic clearance of co-administered drugs. Doses may need to be adjusted accordingly.
Consider:
• expressed wishes of the person and primary carers
• monitoring requirements of the drug (e.g. blood tests) and whether the person will realistically be able to meet them
• swallowing or absorption impairments
• reviewing co-prescribed drugs and taking steps to reduce polypharmacy
• the cardiometabolic 'liability' of the psychotropic drug.
During treatment
Commencing treatment:
• educate the person and their support people about the psychotropic indications for treatment and adverse effects. Communication with formal and informal carers is essential given the central role they often play in monitoring and communicating drug-associated behaviour changes to medical practitioners
• obtain baseline cardiometabolic data
• commence on a low dose and increase gradually.
Monitoring treatment:
• engage the person and their support people in the monitoring process
• set regular review times and a time frame for treatment
• be aware of adverse effects that may be difficult to recognise and report
• watch for behavioural changes after starting treatment or a dose increase as this may indicate adverse effects
• monitor adverse effects on medical comorbidities.
Discontinuing treatment:
• consider discontinuation if treatment is ineffective, there are unacceptable adverse effects, discontinuation is requested, symptoms have resolved or the drug is no longer required
• taper slowly
• avoid simultaneous withdrawal of anticholinergic drugs or multiple psychotropic drugs.
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Full text free online at nps.org.au/australianprescriber VOLUME 39 : NUMBER 4 : AUGUST 2016 syndromes (known as the 'behavioural phenotype'). 10 Knowledge of the behavioural phenotype of a syndrome informs the psychiatric assessment and the need to prescribe. For example, people with Down syndrome commonly talk to themselves and this needs to be differentiated from acute psychosis. Lack of recognition of behavioural phenotypes may result in overdiagnosis of mental illness and inappropriate prescribing. Due to the complexities of diagnosis in this area, consultation with specialist intellectual disability mental health services is recommended.
Prescribing for specific mental disorders
The treatment for specific mental disorders is usually the same as in the general population. Table 2 shows some additional points to consider when prescribing psychotropics to people with mental illness and intellectual disability.
Prescribing in autism spectrum disorder
Identification of psychiatric illness in adults with autism spectrum disorder is challenging and often requires specialist input. The incidence of mental illness in autism is higher than in intellectual disability alone 11 and underdiagnosis of mental illness is a risk. Overdiagnosis is also a concern as the core features of autism can mimic mental disorders (especially psychosis, anxiety and obsessive compulsive disorders) and lead to inappropriate prescribing. and genetic risk factors. Potential barriers to effective cardiometabolic monitoring such as communication difficulties and fear of blood tests should be considered when prescribing. Tailored educational materials 9 for people with intellectual disability and for their formal and informal carers are freely available. These include a cardiometabolic monitoring schedule for people with intellectual disability who have been prescribed psychotropic drugs.
Psychiatric diagnosis in severe intellectual disability
Individuals with more severe levels of intellectual disability or communication difficulties may present atypically, for example with non-verbal or behavioural manifestations of psychiatric disorders. If available, assessment and management by specialised intellectual disability mental health services should be considered for people with more complex or severe levels of intellectual disability. Occasionally, with appropriate consents, psychotropic drugs may be tried when mental illness is considered likely, but is hard to verify. In this case, regular review and close monitoring is required and consultation with a specialist is recommended.
Behavioural phenotypes
Advances in genetics have brought a greater understanding of the typical patterns of behaviour and mental illness seen within many genetic Prescribing psychotropic drugs to adults with an intellectual disability suggest that a high level of off-label prescribing occurs and that the atypical antipsychotics are most frequently prescribed, followed by selective serotonin reuptake inhibitors and mood stabilisers. 16 Given the serious cardiometabolic and other adverse effects associated with many psychotropic drugs, all prescriptions for challenging behaviour should be carefully rationalised and should meet the criteria outlined in current consensus guidelines. 17, 18 Where practical, psychotropic prescribing for challenging behaviour should occur under specialist supervision, and only when:
• the challenging behaviour is severe in nature, persistent and places the person or others at risk
• maximal non-pharmacological interventions have already been tried unsuccessfully
• a drug is likely to treat the problem behaviour • consent for off-label prescription has been obtained, and the person and carers have been informed of any extra financial costs associated with off-label prescription.
Conclusion
Specific evidence for the efficacy of psychotropic drugs in people with intellectual disability and mental illness is lacking. In the absence of a substantial evidence base, clinicians should adapt approaches
There is emerging evidence that psychological strategies (especially mindfulness and cognitive behaviour therapy) have good efficacy in anxiety and depression in autism. The evidence base for psychotropic prescription for mental illness and challenging behaviour in autism is very limited. Any decision to prescribe psychotropic drugs in adults with autism spectrum disorder therefore requires careful consideration of the harms and benefits.
A Cochrane review 12 found that risperidone had short-term efficacy for irritability, social withdrawal hyperactivity, and stereotypic behaviours in children, with suggested similar benefits in adults with autism spectrum disorder. Although risperidone is listed on the Pharmaceutical Benefits Scheme (PBS) for behaviour disorders due to autism in children, its approval in adults is limited to those who commenced risperidone as a child.
There is also a Cochrane review of aripiprazole in children with autism that reported similar shortterm success. 13 However, aripiprazole does not have Therapeutic Goods Administration or PBS approval for autism-related disorders.
Challenging behaviours
Despite the widespread prescribing of psychotropic drugs to treat challenging behaviour in the absence of a defined mental illness, 3 there is little robust evidence to justify this practice. SSRIs are the recommended first-line drugs. Commence on a low dose and increase more slowly than in the general population.
Benzodiazepines should only be used short term when required. They may paradoxically heighten agitation, impulsivity or disinhibition.
Depression
SSRIs are most commonly used in intellectual disability. However they have considerable potential for interacting with other drugs.
Changes in behaviour (e.g. increased aggression, self-injury, repetitive behaviour) may indicate adverse effects or a manic switch.
Bipolar disorderacute mania
Lithium and drugs that require regular serum monitoring should only be commenced if regular blood tests are feasible.
Adjunctive short-term benzodiazepines may also be required. Prescribe lower doses for people with intellectual disability who are older or who have significant physical comorbidities.
ECT may be indicated if initial treatment or subsequent strategies, such as switching psychotropics, are ineffective.
Maintenance includes tailored education and supportive psychological strategies.
Schizophrenia and related psychoses
Consider potential sensitivities, monitoring issues and medical comorbidities. Adverse effects may be more likely due to the higher incidence of comorbid conditions (e.g. physical disorders, congenital anomalies).
Avoid depot psychotropic administration (greater vulnerability to adverse effects such as tardive dyskinesia).
Clozapine may be considered for confirmed cases of treatment-resistant psychosis. Extra precautions include:
• the patient's ability to co-operate with blood tests and other monitoring
• consideration of medical comorbidities such as epilepsy or elevated baseline cardiometabolic risk profile.
SSRIs selective serotonin reuptake inhibitors
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